Chiltern International announced that it has opened a new office in the Chicago area, specifically in Bannockburn, IL.
Barry Simms, Chiltern’s Country Manager, North America, commented, “Chiltern continues to look for opportunities to increase our strategic footprint and we are very excited about our expansion to the greater Chicago area. Our new office is well situated to support our efforts to recruit top-notch staff and be strategically near our clients.”
“We are extremely pleased by the success we have had attracting high-qualified staff to our Bannockburn office, and we welcome our new colleagues to the team,” Dr. Jim Esinhart, Sr. Executive VP, Global Scientific Services, Chiltern, stated. “Our new office supports Chiltern’s mission to deliver high quality services around the world, while demonstrating our commitment to clients’ needs.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.